WuXi Biologics lifts outlook after profit jump

WuXi Biologics posted H1 2025 revenue of RMB 9.95 billion, up 16.1% YoY, with IFRS net profit rising 54.8%. EBITDA grew 50.5% and gross margin reached 42.7%. The company added a record 86 new integrated projects and raised its FY25 revenue growth target to 14–16%, citing demand for complex biologics and late-stage manufacturing.